Find a trial

To make an enquiry or register your interest in a current pulmonary fibrosis clinical trial, please complete the patient enquiry form here.

Deciding to be part of a clinical trial is a very personal decision. People eligible to participate in a clinical trial are limited to a group with very specific characteristics. Please see below clinical trials that are currently recruiting in Australasia.

Recruiting Trials

Trial	Title	Status	More Information
Novartis LTP001	A participant and investigator-blinded, randomized, placebo-controlled, multicentre, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT05497284
Lassen Therapeutics 1 LASN01	A Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to determine the safety, tolerability, immunogenicity and pharmacokinetic properties of LASN01 in healthy subjects and in patients with idiopathic pulmonary fibrosis or thyroid eye disease	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT05331300
Boehringer Ingelheim BI 1305-0023	A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1305-0023 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT05321082
SINFONIA	A clinical trial examining the benefits of SingINg For breathing in COPD aNd ILD pAtients	Recruiting	Trial Summary anzctr.org.au ID: Phase III - ACTRN12621001280897
SHIELD	The SHIELD Whole Lung Lavage Observational Cohort Study	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT05402176
SNDX-6352-0506	A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	Not yet recruiting	Trial Summary
TELO-SCOPE	Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis.	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT04638517
PFOX	PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT03737409
HIIT	High intensity interval training in fibrotic interstitial lung disease	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT03800914
GRIPF	Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF)	Recruiting	Trial Summary Clinicaltrials.gov ID: Not Applicable

If you would like to take part in a clinical trial or find out more about currently recruiting clinical trials email the PACT coordinator on pactcoordinator@cre-pf.org.au

Trials Closed to Recruitment

Trial	Title	Status	More Information
Endeavor Biomedicines ENV-101	A phase 2, multi-center study evaluating the safety and efficacy of ENV-101 (taladegib) in subjects with idiopathic pulmonary fibrosis (IPF)	Closed to Recruitment	Clinicaltrials.gov ID: NCT04968574
Boehringer Ingelheim BI 1305-0014	A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)	Closed to Recruitment	Clinicaltrials.gov ID: NCT05321069
STARSCAPE WA42293	A phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis.	Closed to Recruitment	ClinicalTrials.gov ID: NCT04552899
GALACTIC-1	A randomised, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in participants with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler (DPI) over 52 weeks.	Closed to Recruitment	Clinicaltrials.gov ID: NCT03832946
BI 1305-0013	Title: A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.	Closed to Recruitment	Clinicaltrials.gov ID: NCT04419506
ATLAS AP01-002	A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis	Closed to Recruitment	Clinicaltrials.gov ID: ACTRN12618001838202
Trail1	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD)	Closed to recruitment The TRAIL1 study continued enrolment through the planned timeline, but was somewhat impacted by COVID and did not meet enrolment goals.	Clinicaltrials.gov ID: NCT02808871
AGN120-1	An Open Label Study of the Efficacy, Safety and Tolerablity of Np-120 on Idiopathic Pulmonary Fibrosis and its Associated Cough	Closed to Recruitment	Clinicaltrials.gov ID: NCT04318704
Zephyrus FGCL-3019-091	FGCL-3019-091 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF).	Closed to recruitment	Clinicaltrials.gov ID: NCT03955146
BMS IM027-040	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis.	Closed to recruitment

Completed Trials

Trial	Title	Status	More Information
HHF-ILD	Handheld fan for breathlessness in interstitial lung disease	Study completed	Clinicaltrials.gov ID: ACTRN12618001949279
COLDICE	Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease allianCE	Study completed	Clinicaltrials.gov ID: ACTRN12615000718549

Discontinued Trials

Trial	Title	Status	More Information
SCENIC	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Discontinued The SCENIC study was terminated due to the impact of COVID-19. The study was being conducted across 11 countries and while the impact was minimal in Australasia this was not the case in the other regions.	Clinicaltrials.gov ID: NCT03864328
Isabela 1&2	A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis	Discontinued The decision to discontinue the ISABELA Phase 3 clinical studies was based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies.	Clinicaltrials.gov ID: NCT0371l-162 Clinicaltrials.gov ID: NCT03733444
Blade Therapeutics	A Phase 1a/1b, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BLD-2660 in Healthy Volunteers and Subjects with Lung Fibrosis or Liver Fibrosis	Discontinued	Clinicaltrials.gov ID: NCT03559166
SPIRIT	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Discontinued	ClinicalTrials.gov ID: NCT03573505